Searched for
ACHIN GUPTA
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Cipla Q4 net profit slumps 55% YoY to Rs 555 crore, full-year PAT down 26%Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income also saw a 3% decrease. For the f...
- Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividendCipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- Cipla plans deeper push in domestic market and chronic therapies over next 2–3 yearsCipla's incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presenc...
- Cipla launches inhalable insulin for diabetes careCipla has launched a new orally inhaled insulin powder for diabetes patients in India. This needle-free alternative to injections offers a ...
- Cipla, Pfizer ink partnership for exclusive marketing of four brands in IndiaPfizer India and Cipla Limited have announced a strategic partnership where Cipla will exclusively market and distribute four of Pfizer's k...
- Cipla launches drug for obesity, diabetesCipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...
- Cipla launches India's first dedicated lung health diagnostics centreCipla has opened India's first integrated lung diagnostics and wellness centre in Lajpat Nagar, Delhi. This facility offers over 60 tests f...
- Cipla global CEO Umang Vohra to step down; Achin Gupta to take overCipla's global CEO Umang Vohra will step down in March 2026. Achin Gupta, currently global COO, will take over as the new MD and GCEO from ...
- Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug YurpeakIn an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...
- Cipla ups investment in point-of-care testing firm Achira LabsCipla has announced further investment of up to Rs 26 crore in Achira Labs, a company specializing in point-of-care medical test kits. This...
- Cipla launches diagnostic device for multiple health conditionsThe company said with the device the company has expanded its product offerings for diagnostics laboratories and aims to bridge the current...
- Glenmark Pharma launches COPD treatment inhaler in UKDrug firm Glenmark Pharma on Tuesday announced the launch of Tiotropium Bromide Dry Powder Inhaler, used in the treatment of chronic obstru...
- Glenmark Pharma to launch its nasal spray Ryaltris in EUThe drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and wate...
- Have I picked up the right mutual funds to invest for 15 years?If you have any mutual fund queries, message on ET Mutual Funds on Facebook. We will get it answered by our panel of experts.
- Glenmark Pharma rallies on Germany marketing nodThe drug, Fluticasone/Salmeterol dry powder inhaler (DPI), is a generic version of GlaxoSmithKline’s Seretide Accuhaler.
- Glenmark inks licensing pact for generic Tiotropium Bromide dry powder inhaler in Western EuropeThis is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler, the ...
Load More
